Clinical Trial Update: Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated neoadjuvant temsirolimus (CCI-779) followed by radical prostatectomy in men with newly diagnosed high-risk prostate cancer, and the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Torisel (Temsirolimus)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED